New insider activity at CME Group ( (CME) ) has taken place on February 23, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CME Group director Bryan Durkin has recently offloaded 4,200 shares of the company’s stock in a transaction valued at $1,300,530. The sale highlights a notable insider move at the derivatives marketplace operator, drawing attention to trading activity within the company’s leadership ranks.
Recent Updates on CME stock
CME Group shares reacted to a strong Q4 and full‑year report featuring record average daily volumes, solid revenue and EPS growth, and industry‑leading margins, which support a constructive fundamental view. Analysts’ latest price target revisions center on CME’s ability to sustain volume and data growth while absorbing higher tech and product investments, amid regulatory and execution risks around new clearing, crypto, and prediction‑market initiatives.
Spark’s Take on CME Stock
According to Spark, TipRanks’ AI Analyst, CME is a Outperform.
The score is driven primarily by strong financial performance (high margins and low leverage) and a constructive earnings outlook supported by record activity, pricing actions, and capital returns. Offsetting factors are a relatively high valuation and technically overbought momentum signals that raise near-term volatility/pullback risk.
To see Spark’s full report on CME stock, click here.
More about CME Group
YTD Price Performance: 11.29%
Average Trading Volume: 1,988,784
Technical Sentiment Signal: Buy
Current Market Cap: $109.1B